WHITEHOUSE STATION, N.J., and DANVILLE, Pa., June 18, 2012 – Geisinger Health System and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a new multi-year collaboration designed to improve patient health outcomes by focusing on innovative solutions that facilitate shared decision making between patients and physicians and improve adherence to treatment plans and clinical care processes.

“We believe that healthcare is most effective when patients are active partners in their care,” said Glenn Steele Jr., M.D., Ph.D., president and chief executive officer of Geisinger Health System. “Our collaboration with Merck will allow both organizations to leverage our individual expertise and joint resources to improve patient engagement, including finding new interventions to increase the likelihood that patients will adhere to their treatment plans.”

Teams from Geisinger and Merck will work together to improve patient adherence, increase the role of patients in making decisions to help manage their conditions, share information among extended care teams, and improve clinical care processes. The first tool being developed is an interactive web application designed to help primary care clinicians assess and engage patients at risk for cardiometabolic syndrome. Cardiometabolic syndrome is a clustering of various risk factors that put an individual at risk of developing type 2 diabetes and cardiovascular disease.

“When you have two leading healthcare companies that share a commitment to improve health outcomes and are focused on fundamental problems that have plagued the healthcare system for years, the results have the potential to be transformative," said Mark Timney, Merck's President of Global Human Health – U.S. Market. "We're excited about the opportunity to work with Geisinger to address these critical areas."

The web application and other care management solutions that Merck and Geisinger develop will initially be tested within the Geisinger system. Geisinger has been at the forefront of the development of innovative healthcare delivery models focused on improving adherence and developing methods to better engage patients. Merck has conducted scientific research to better understand the drivers of non-adherence and develop evidence-based interventions.

”A rapid learning process will be used to integrate, evaluate and improve the performance of each solution in primary care clinical settings," Dr. Steele said. "We will closely monitor patient acceptance, treatment adherence, and other metrics to determine which tools and solutions have the ability to improve patient care and are ready to be deployed on a broader scale.”

About Geisinger Health System
Geisinger is an integrated health services organization widely recognized for its innovative use of the electronic health record, and the development and implementation of innovative care models including ProvenHealth Navigator, an advanced medical home model, and ProvenCare program. The system serves more than 2.6 million residents throughout 44 counties in central and northeastern Pennsylvania. For more information, visit www.geisinger.org. Follow the latest Geisinger news and more at Twitter and Facebook.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.